Cas:7498-65-9 bis(4-chloro-3-nitrophenyl)methanone manufacturer & supplier

Chemical Name:bis(4-chloro-3-nitrophenyl)methanone

CAS.NO:7498-65-9

Synonyms:4,4′-dichloro-3,3′-dinitro-benzophenone;3,3′-dinitro-4,4′-dichloro benzophenone;4,4′-Dichlor-3,3′-dinitro-benzophenon;T0514-2521

Molecular Formula:C₁₃H₆Cl₂N₂O₅

Molecular Weight:341.10300

HS Code:

Physical and Chemical Properties:

Melting point:132-134ºC(lit.)

Boiling point:521.9ºC at 760mmHg

Density:1.585g/cm3

Index of Refraction:1.654

PSA:108.71000

Exact Mass:339.96500

LogP:5.08720

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 3077 9/PG 3

Packing Group:

Contact us for information like 4,4′-dichloro-3,3′-dinitro-benzophenone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,T0514-2521 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4,4′-dichloro-3,3′-dinitro-benzophenone Use and application,3,3′-dinitro-4,4′-dichloro benzophenone technical grade,usp/ep/jp grade.

Related News: Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2). bis(4-chloro-3-nitrophenyl)methanone manufacturer There are more than 4,700 different PFAS chemical compounds, researchers said. Since the 1950s, they have been widely used in a number of consumer products, including stain-repellent fabrics, nonstick cookware, polishes, waxes, paints and cleaning products, according to the U.S. Environmental Protection Agency. bis(4-chloro-3-nitrophenyl)methanone supplier Same as Imbruvica’s original monotherapy use, the Venclexta combo offers a convenient oral treatment, while the drug’s two other approved cocktails—with Gazyva or Roche’s Rituxan—involve infusions. bis(4-chloro-3-nitrophenyl)methanone vendor Without disclosing or confirming the number of vaccine doses, the FDA said in a news release that it had authorized two batches of the vaccine for use, that several other batches were not suitable for use and that others were being evaluated. bis(4-chloro-3-nitrophenyl)methanone factory Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).